Wall Street Experts
ver. ZuMIgo(08/25)
Prognozy (mln) dla Lotus Pharmaceutical Co., Ltd.
| Okres |
2023-12-31 |
2024-12-31 |
2025-12-31 |
2026-12-31 |
| Przychód (średnia) |
16,632.26 |
18,873.43 |
20,953.67 |
26,884.17 |
| Przychód Δ r/r |
0.00% |
13.47% |
11.02% |
28.30% |
| Przychód (min) |
15,623.08 |
18,285.68 |
19,130.16 |
25,252.96 |
| Przychód (max) |
17,596.17 |
19,098.53 |
23,028.50 |
28,442.24 |
| EBITDA (średnia) |
4,553.84 |
5,167.46 |
5,737.02 |
7,360.77 |
| EBIT (średnia) |
3,470.95 |
3,938.65 |
4,372.77 |
5,610.39 |
| EBIT % |
20.87% |
20.87% |
20.87% |
20.87% |
| Zysk netto (średni) |
3,948.00 |
4,956.33 |
6,170.33 |
4,113.78 |
| Zysk netto % |
23.74% |
26.26% |
29.45% |
15.30% |
| EPS (średnia) |
15.10 |
18.92 |
23.70 |
15.70 |
| Liczba analityków (Przychody) |
6 |
7 |
3 |
2 |
| Liczba analityków (EPS) |
6 |
7 |
3 |
1 |
| symbol |
1795.TW |
1795.TW |
1795.TW |
1795.TW |